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SUMMARY 
Depressive mood is a common accompaniment of schizophrenia. The present study was taken up 
with the aim to study the effect of imipramine on depressivse symptoms of schizophrenia. Eighteen 
patients of schizophrenia with depressive symptoms were studied under a double blind controlled 
design with a chlorpromazine-imipramine and a chlorpromazine-ptacebo grcup. Both the groups 
showed significant improvement (p<.001) after the 6 week trial and the addition of imipramine to 
chlorpromazine therapy did not have any advantageous or deleterious effect. 
Depressive symptoms are a common 
accompaniment of schizophrenia (Knights 
and Hirsch, 1981; Roy et al., 1983; 
Elk et al., 1986). Postpsychot'c depression 
has been extensively studied (Johnson, 
1981; Knights and Hirsch, 1981; Moller 
and Zerssen, 1981) but not many resear-
chers have specifically evaluated the treat-
ment strategies for managing depressive 
symptomatology during the course of 
schizophrenia. There are a number of 
studies which have used phenothiazines in 
combination with antidepressants for the 
treatment of schizophrenia. These have 
been reviewed by Siris et al. (1978) who 
concluded that majority of the studies 
have unfavourable responses and many of 
them employed low doses of antidepres-
sants. 
It has been observed that a large 
number of psychiatrists do use combina-
tions of phenothiazines and antidepres-
sants during the treatment of schizophre-
nia, so it was thought worthwhile to study 
the role of addition of imipramine to 
phenothiazines in a group of schizophri-
nics who show marked depressive 
symptoms. The aim of the study was to 
evaluate the role of imipramine in treating 
the depressive symptoms in schizophrenia. 
MATERIAL AND METHOD 
The sample for the study was selected 
from the patients admitted to the inpa-
tient facility of the Department of 
Psychiatry, K.G.'s Medical College, 
Lucknow. 
The patients between 17 and 45 years 
of age fullfUling Research Diagnostic 
Criteria for schizophrenia (Spitzer et al., 
1978) who had not received neuroleptics 
and/or ECT's for the present episode, were 
screened after 7 days of phenothiazine 
treatmest on Hamilton Rating Scale for 
Depression and those who scored 17 or 
more were included in the study. Any 
patient needing parenteral medication or 
ECT's, having any other psychiatric dis-
order, pregnancy or physical illness was 
excluded. Informed consent was obtained 
from all patients or their relatives for 
participation in the trial. 
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On day 1, the patients fulfilling RDG 
for schizophrenia (Spitzer et al., 1978) 
were evaluated on Modified Brief Psychia-
tric Rating Scale "MBPRS" (Overall & 
Gorham, 1962) and Signs/Symptoms Scale 
for neuroleptics "SSS" (WHO, 1986). 
They were put on 8o0 mg Chlorproma-
zine in 2/3 divided doses alongwith 
trihexiphenidyl 2 mg thrice daily after 
evaluation. On day 7, patients who were 
found to be amenable for the administra-
tion of Hamilton Rating Scale for Depre-
ssion "HRSD" (Hamilton, 1960) were 
evaluated on it. If they scored 17 or more 
on this scale, they were finally included in 
the study. They were also assessed on 
MBPRS, SSS, and Side effect rating scale 
for antidepressants "SERS" (Asberg 
et al., 1970). These patients were divided 
into 2 groups on a double blind basis, one 
group received imipramine 75 mg bed 
time and the other group a similar capsule 
of placebo material. Both the groups 
continued receiving chlorpromazine and 
Trihexiphenidyl. Weekly assessments were 
then made for both the groups on 
MBPRS, HRSD, SSS and SERS for 6 
weeks. The dosage of GPZ was increased 
to 1200 mg/day and the dose of imipra-
mine/placebo was doubled if scores on 
MBPRS or HRSD showed less than 50% 
improvement after 3 weeks of their res-
pective treatments. The study was ter-
minated on day 49. 
OBSERVATIONS 
Out of a total number of 89 patients 
who were assessed on HRSD on day 7, 
only 19 patients scored 17 or more and 
were included in the study. One patient 
absconded and could not complete the 
study. The experimental and control 
groups comprised of 9 patients each. The 
results were analysed statistically by using 
paired 't' test, Pearson's Product Moment 
Correlation Coefficient and Analysis of 
Govariance. Statistically significant im-
provemnt (p<.001) was observed in 
both the groups (Fig. 1 and 2). There was 
no statistically significant difference in 
improvement on MBPRS and HRSD in 
groups treated with imipramine or 
placebo. The effect of imipramine was 
also evaluated on individual items of 
HRSD but no significant difference from 
placebo treated group was observed. 
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Table I shows weekly improvement 
on HRSD total scores and MBPRS-
ANDP* subscores from the baseline with 
*ANDP: Anxiety-Depression Category of MBPRS 
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TABLE I—Weekly correlation between improvemtnts on total HRSD scores and MBPRS minus 
(ANDP) subscores 
Weeks 
Exp. group Cont. group 
Mean Improvement From Baseline Mean Improvement from baseline 
MBPRS HRSD r Sig. MBPRS HRSD r Sig. 
WUIUJ-(ANDP) m«BW-(ANDP) 
After 
After 
After 
After 
After 
After 
1 WK. 
2WK. 
3 WK. 
4 WK. 
5WK. 
6WK. 
1.77 
7.77 
6.88 
8,33 
10.11 
11.88 
7.33 
11.88 
11.88 
13.11 
12.0 
14.88 
0.02 NS 
0.47 NS 
0.53 NS 
0.64 NS 
0.52 NS 
0.32 NS 
4.55 
6.77 
11.11 
10.44 
11.77 
12.33 
8.22 
9.6C 
12.22 
11.22 
12.0 
13.66 
0.31 NS 
0.68 P<0.05 
0.26 NS 
0.45 NS 
0.13 NS 
0.58 NS 
their coefficients of correlation. ANDP 
subscore was deducted from total MBPRS 
scores to minimize the overlap of symptoms 
between the 2 scales (MBPRS and 
HRSD) and to find out the relationship 
of improvements in psychotic and depre-
ssive symptoms after every week of treat-
ment. The coefficiect of correlation was 
positive in both the groups. When these 
coefheients of correlation were compared 
between the two groups, they were found 
to be insignificant.The side-effects in both 
the groups were usually of mild to moderate 
degree and gradually reduced in severity 
during the course of treatment without 
any additional pharmacological interven-
tion (Table II). Imipramine treated 
group did not exhibit more side-effects 
than the group receiving placebo. 
DISCUSSION 
Factors which often confound the 
issue of depression in schizophrenia are 
diagnostic laxity, use of illdefined criteria 
for identifying schizophrenia, imprecise 
techniques used for identifying and 
measuring depressive symptoms, inclusion 
of subjects already treated with neurolep-
tics and inadequate length of time for 
which patients are observed (Hirsch, 1982; 
Galdi, 1983). In the present study most of 
the above mentioned pitfalls were avoided 
by using Research Diagnostic Criteria, 
evaluating depression on a standardized 
depression rating scale, objectively measu-
ring improvement and by employing 
adequate dosage and duration of anti-
depressant and neuroleptic. 
This study may be criticized because 
of a small sample size. This sample size 
was mainly due to the fact that large 
number of patients were excluded as they 
scored less than 17 on HRSD but tin's 
high cut-off point was essential as there 
are 10 items in this scale which are 
common with the symptomatology of 
schizophrenia, so a number of cases who 
would not even be depressed could score 
atleast 10 on it. Therefore, a minimum 
score of 17 was considered nece»s;uy to 
identify depressive s^-mptomatoloqrv in 
schizophrenia. 
The scores on MBPRS and HRSD 
improved significantly in both the groups 
and continued to do so till the end of the 
study. This indicates that the addition 
of imipramine did not have adverse effect 
on the symptomatology of schizophrenia 
nor did it have any additional beneficial 
effect on the depressive symptoms of these 232  DINESH DUA *t al. 
TABLE II—Common side effects and their severity 
Side-effects 
Drowsiness 
Tremors 
Blurring of vision 
Orthostatic symp. 
Dizziness 
Constipation 
Dryness of mouth 
Weight gain 
Phys. tiredness 
Mict. disturbances 
Palpitation 
Headach 
Akathesia 
Mild 
2 
8 
6 
6 
6 
3 
1 
7 
3 
6 
6 
4 
0 
Exp. group 
Mod. 
7 
1 
2 
2 
2 
4 
5 
0 
2 
0 
0 
1 
2 
Sev. 
0 
0 
0 
0 
0 
0 
0 
0 
1 
0 
0 
0 
0 
Mild 
3 
7 
7 
9 
2 
3 
2 
6 
3 
3 
6 
8 
5 
Gont. group 
Mod. 
6 
1 
0 
0 
2 
2 
7 
0 
2 
0 
0 
0 
0 
Sev. 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
, 
t. 
patients. This is in line with the findings 
of Becker (1983) who also failed to find 
any significant difference between the two 
groups although in his study, the two 
groups comprised of one receiving chlor-
promazine-imipr amine combination and 
the other thiothexene. Knights and 
Hirsch (1981) also stated that the depre-
ssive symptoms of schizophrenia decrease 
in severity with effective neuroleptic 
treatment alone. However, Prusoff et al. 
(1979) and Hanlon et al. (1970) reported 
that perphenazine-amitriptylinc and flu-
phenaz'ne-imipramine combinations res-
pectively were better than either of the 
neuroleptics alone in the treatment of 
schizophrenia. These two studies arc 
actually not comparable with the present 
one as the study by Prusoff et al. (1979) 
included only chronic schizophrenics after 
one month of perphenazine treatment 
where the possibility of pharmacogenic 
depression can not be ruled out and more-
over the two compounds used were diffe-
rent. On the other hand Hanlon et al. 
(1970) included all newly admitted psy-
chiatric patients without considering the 
presence or absence of depression as a part 
of their symptomatology. 
In the present study, the addition of 
imipramine to chlorpromazine treatment 
also failed to show any advantage with 
regard to the individual items of HRSD 
nor did it have any beneficial effect on 
either MBPRS-ANDP subscores or 
HRSD total scores. This observation 
again substantiated the finding that 
chlorpromazine-imipramine and chlorpro-
mazine-place bo combinations respectively 
have identical effects on psychotic as well 
as depressive symptoms of schizophrenia. 
Casey ct al. (1961), Kurland et al. (1971), 
Hanlon et al. (1969) and Chuinard et al. 
(1975) also reported that the combination 
of neuroleptic and antidepressant is not 
superior to neuroleptic alone in cases of IMIPRAMINE IN DEPRESSED SCHIZOPHRENICS  233 
schizophrenia. But all the above men-
tioned studies have tried the combination 
on acute or chronic schizophrenics with no 
regard to depressive symptomatology, 
thereby making these studies, in fact, 
incomparable with the present one. 
However, they do agree with the present 
observations that addition of antidepre-
ssants does not substantially improve the 
course of schizoprenia nor does it produce 
any deterioration, which is also evident 
from the present observation that the com-
bination therapy did not lead to any 
additional side-effects especially central 
anticholinergic toxicity(Extein and Bowers, 
1975) which could have been termed as 
alarming. 
The overall results of the present 
study indicate that the depressive symp-
toms of schizophrenia abate by themselves 
with the improvement in psychosis and 
the addition of imipramine does not prove 
beneficial. This addition of antidepre-
ssant to neuroleptic treatment also does 
not deteriorate the course of schizophrenia 
nor does it produce any undesirable-
side-effects. However, the use of imipra-
mine in schizophrenia cannot be written 
off on the basis of the present study as it 
was carried out on a small group of 
patients. It will be worth-wh'Je to study 
different groups of schizophrenia i. e. 
acute and chronic, with or without depre-
ssion for longer periods, to definitely 
establish the role of antidepressants in the 
treatment of schizophrenia. 
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